Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics

• Published in: International journal of pharmaceutics Vol. 489; no. 1-2; pp. 83 - 90
• Main Authors: Li, Yu-Ji, Dong, Ming, Kong, Fan-Min, Zhou, Jian-Ping
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.07.2015
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Cell Line, Tumor; Cell Survival - drug effects; Drug Carriers - administration & dosage; Drug Carriers - chemistry; Drug Liberation; Folic Acid - administration & dosage; Folic Acid - chemistry; Humans; Iron - administration & dosage; Iron - chemistry; Liver cancer; Liver Neoplasms - drug therapy; Magnetic nanoparticles; Magnetic Phenomena; Magnetic resonance imaging; Nanomedicine; Nanoparticles - administration & dosage; Nanoparticles - chemistry; Niacinamide - administration & dosage; Niacinamide - analogs & derivatives; Niacinamide - chemistry; Phenylurea Compounds - administration & dosage; Phenylurea Compounds - chemistry; PLGA; Polyesters - administration & dosage; Polyesters - chemistry; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - chemistry; Sorafenib; Liver cancer; PLGA; Magnetic resonance imaging; Nanomedicine; Sorafenib; Magnetic nanoparticles
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2015.04.028

[Display omitted] Nanoparticulate system with theranostic applications has attracted significant attention in cancer therapeutics. In the present study, we have developed a novel composite PLGA NP co-encapsulated with anticancer drug (sorafenib) and magnetic NP (SPION). We have successfully developed nanosized folate-conjugated PEGylated PLGA nanoparticles (SRF/FA–PEG–PLGA NP) with both anticancer and magnetic resonance property. We have showed that FA-conjugated NP exhibits sustained drug release and enhanced cellular uptake in BEL7402 cancer cells. The targeted NP effectively suppressed the tumor cell proliferation and has improved the anticancer efficacy than that of free drug or non-targeted one. Additionally, enhanced MRI properties demonstrate this formulation has good imaging agent characteristics. Finally, SRF/FA–PEG–PLGA NP effectively inhibited the colony forming ability indicating its superior anticancer effect. Together, these multifunctional nanoparticles would be most ideal to improve the therapeutic response in cancer and holds great potential to be a part of future nanomedicine. Our unique approach could be extended for multiple biomedical applications.